Dupilumab significantly improves itch and skin lesions in patients with prurigo nodularis: Pooled results from two phase 3 trials (liberty-pn prime and prime2)

被引：0
|
作者：
Yosipovitch, G. [7 ]
Kwatra, S. G. [9 ]
Mollanazar, N. [1 ]
Staender, S. [2 ]
Satoh, T. [3 ]
Laws, E. [4 ]
Mannent, L. P. [5 ]
Mortensen, E. [6 ]
Maloney, J. [6 ]
Shi, G. [4 ]
Bansal, A. [6 ]
Martincova, R. [8 ]
机构：
[1] Univ Penn, Philadelphia, PA USA
[2] Univ Hosp Munster, Munster, Germany
[3] Natl Def Med Coll, Tokorozawa, Saitama, Japan
[4] Sanofi, Bridgewater, NJ USA
[5] Sanofi, Chilly Mazarin, France
[6] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[7] Univ Miami, Miami, FL USA
[8] Sanofi, Prague, Czech Republic
[9] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2023年 / 143卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
650
引用
收藏
页码：S111 / S111
页数：1
相关论文
共 33 条
  • [21] Ixekizumab Treatment Significantly Improves Enthesitis and Dactylitis in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Trials
    Gladman, Dafna D.
    Orbai, Ana-Maria
    Gallo, Gaia
    Birt, Julie
    Rathmann, Suchitrita
    Marzo-Ortega, Helena
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [22] Dupilumab in patients with moderate-to-severe atopic dermatitis and comorbid asthma requiring treatment: Analysis from two pooled phase 3 trials (liberty ad solo 1&2)
    Beck, L. A.
    Deleuran, M.
    Guttman-Yassky, E.
    Kingo, K.
    Chen, Z.
    Graham, N. M. H.
    Pirozzi, G.
    Eckert, L.
    Gadkari, A.
    Ardeleanu, M.
    ALLERGY, 2018, 73 : 76 - 77
  • [23] Dupilumab Improves General Health-Related Quality-of-Life in Patients with Moderate-to-Severe Atopic Dermatitis: Pooled Results from Two Randomized, Controlled Phase 3 Clinical Trials
    Eric L. Simpson
    Dermatology and Therapy, 2017, 7 : 243 - 248
  • [24] Dupilumab Improves General Health-Related Quality-of-Life in Patients with Moderate-to-Severe Atopic Dermatitis: Pooled Results from Two Randomized, Controlled Phase 3 Clinical Trials
    Simpson, Eric L.
    DERMATOLOGY AND THERAPY, 2017, 7 (02) : 243 - 248
  • [25] Dupilumab Treatment Improves Sense of Smell in Patients With Chronic Rhinosinusitis With Nasal Polyps - Pooled Results From the SINUS-24 and SINUS-52 Phase 3 Trials
    Mullol, Joaquim
    Han, Joseph
    Bosso, John
    Mannent, Leda
    Amin, Nikhil
    Cho, Seong
    Bachert, Claus
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB169 - AB169
  • [26] Lebrikizumab monotherapy improves quality of life through improvement in itch and sleep: Results from two Phase 3 trials in patients with moderate-to-severe atopic dermatitis
    Yosipovitch, Gil
    de Bruin-Weller, Marjolein
    Wiseman, Marni
    Elberling, Jesper
    Gutermuth, Jan
    Pierce, Evangeline
    Montmayeur, Sonia
    Ding, Yuxin
    Yang, Emily
    Chisolm, Sarah
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB61 - AB61
  • [27] Dupilumab significantly reduces itch and hives in patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite use of standard-of-care antihistamines: Results from a phase 3 trial (LIBERTY-CSU CUPID study A)
    Maurer, Marcus
    Casale, Thomas B.
    Saini, Sarbjit S.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB46 - AB46
  • [28] Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials
    Bachert, Claus
    Han, Joseph K.
    Desrosiers, Martin
    Hellings, Peter W.
    Amin, Nikhil
    Lee, Stella E.
    Mullol, Joaquim
    Greos, Leon S.
    Bosso, John V.
    Laidlaw, Tanya M.
    Cervin, Anders U.
    Maspero, Jorge F.
    Hopkins, Claire
    Olze, Heidi
    Canonica, G. Walter
    Paggiaro, Pierluigi
    Cho, Seong H.
    Fokkens, Wytske J.
    Fujieda, Shigeharu
    Zhang, Mei
    Lu, Xin
    Fan, Chunpeng
    Draikiwicz, Steven
    Kamat, Siddhesh A.
    Khan, Asif
    Pirozzi, Gianluca
    Patel, Naimish
    Graham, Neil M. H.
    Ruddy, Marcella
    Staudinger, Heribert
    Weinreich, David
    Stahl, Neil
    Yancopoulos, George D.
    Mannent, Leda P.
    LANCET, 2019, 394 (10209): : 1638 - 1650
  • [29] EVOLUTION OF EASI RESPONSE WITH LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO- SEVERE ATOPIC DERMATITIS: POOLED RESULTS FROM TWO PHASE 3 TRIALS (ADVOCATE1 AND ADVOCATE2) AT WEEK 16
    Wollenberg, Andreas
    Warren, Richard B.
    Silverberg, Jonathan I.
    Guttman-Yassky, Emma
    Thaci, Diamant
    Irvine, Alan D.
    Gold, Linda Stein
    Blauvelt, Andrew
    Simpson, Eric L.
    Chu, Chia-Yu
    Liu, Zhuqing T.
    Lima, Renata Gontijo
    Pillai, Sreekumar
    Gil, Esther Garcia
    Seneschal, Julien
    ACTA DERMATO-VENEREOLOGICA, 2023, 103 : 53 - 53
  • [30] Ixekizumab treatment improves skin-related sexual difficulties in patients with moderate-to-severe plaque psoriasis: integrated results from three Phase 3 trials (UNCOVER-1,-2 and-3)
    Guenther, L. C.
    Foley, P.
    Cather, J.
    Bleakman, A. Potts
    Burge, R.
    Zhu, B.
    van de Kerkhof, P.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 79 - 80
1234